Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
Executive Summary
Report sponsored by Association for Accessible Medicines in US says drugs with restricted distribution programs had total sales of $22.7bn in 2016; seven drugs had sales topping $1bn.
You may also be interested in...
Unapproved Uses Bill May Eventually Pass, But Would Likely Need Additional Safeguards
Off-label communication amendments tabled at House markup of user fee legislation after Democrats object; the two sides agreed to discuss the issue further down the road.
Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting
Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
Sen. Leahy's reintroduced CREATES Act allows generic sponsors to sue innovators who fail to provide sufficient quantities of REMS covered products, but seems to give wide latitude to courts; bill reflects Congress' broader focus on generic drugs to address drug pricing issue.